Currently Enrolling Trials
PhosLo (calcium acetate) is a phosphate binder.
PhosLo is specifically indicated for the reduction of serum phosphorus in patients with end stage renal disease.
PhosLo is supplied as a gelcap. Starting dose is 2 gelcaps with each meal. Titrate the dose every 2-3 weeks until acceptable serum phosphorus level is reached. Most patients require 3-4 gelcaps with each meal.
Mechanism of Action
PhosLo (calcium acetate) binds to the phosphate taken in through one's diet to form insoluble calcium phosphate. This is then excreted from the body without being absorbed.
Adverse events associated with the use of PhosLo capsules or gelcaps may include (but are not limited to) the following:
- Stomach pains
Clinical Trial Results
Studies have confirmed that using calcium acetate as a phosphorus binder will control serum phosphorus levels in most dialysis outpatients.